our ventures

We help life sciences and health tech companies propel their innovative ideas forward. From market-ready companies in the beginning stages to more established life sciences companies, we provide the facilities, expertise, and support growing health ventures need to succeed.

HUB 1 Ventures

Based in Edmonton, DynaLIFE provides clinical laboratory services for northern Alberta. Recently they have been expanding operations to help increase COVID testing in the province. DynaLIFE is HUB 1’s flagship tenant.

Calgary-based Syantra Inc. is a venture-backed company with a blood test for breast cancer detection currently in world-wide clinical studies.

TapLabs makes clinical lab work easy. Professional technicians provide same-day lab collection services to Calgary homes or offices seven days a week.

NanoTess is revolutionizing nanotechnology to solve the world's toughest health challenges beginning with chronic wounds.  NanoTess' approach is unique and focuses on the use of nanocatalysts as small and mighty solutions to address unmet health needs.

Karen Matthews provides management consulting and Quality Management Systems that plan, control, and improve the elements that impact results in laboratory environments.

All Skin is a dermatologist-developed health technology company providing personalized skincare recommendations using data science, machine learning and home testing kits.

Research has shown that the gut microbiome plays a key role in health, but it’s difficult to access. Nimble Science is transforming personalized health by facilitating easier access to the gut microbiome.

International Ventures

Inogenix Inc. is South Korean AI-based molecular diagnostic company developing advanced biotechnology. It has more than 40 patents for molecular diagnosis technology related to oncology, infectious diseases, and genetic diseases, and it is actively conducting joint research with a number of bio companies, research institutes and medical institutions around the world.

learn more

FatiAbGen is focusing on discovering and developing innovative monoclonal antibody-based recombinant immunotoxin therapeutics for the treatment of various cancers as well as immunological disorders and infectious diseases using FatiAbGen’s antibody engineering technologies.

learn more